SCHEMBL23945966

SCHEMBL23945966

CC(C)CCCOCCOCCOCCOCC(=O)NCCCC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.36
RECQL P46063 1/20 0.36
GLP1R P43220 5/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
HPGD P15428 1/20 0.34
MAPT P10636 3/20 0.33
ALDH1A1 P00352 1/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HTT P42858 1/20 0.32
HSD17B10 Q99714 2/20 0.32
EPHX2 P34913 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24673317 0.88 TSHR (0.40) TSHRRECQLGLP1RKMT2AMEN1
SCHEMBL22526077 0.88 TSHR (0.40) TSHRRECQLGLP1RKMT2AMEN1
SCHEMBL24672702 0.88 TSHR (0.40) TSHRRECQLGLP1RKMT2AMEN1
SCHEMBL23945414 0.85 HPGD (0.40) TSHRRECQLKMT2AMEN1HPGD
SCHEMBL25832916 0.84 TSHR (0.47) TSHRRECQLGLP1RMAPTALDH1A1
SCHEMBL25122630 0.84 TSHR (0.47) TSHRRECQLGLP1RMAPTALDH1A1
SCHEMBL25123197 0.84 TSHR (0.47) TSHRRECQLGLP1RMAPTALDH1A1
SCHEMBL23807126 0.83 FAAH (0.49) TSHRRECQLGLP1RMAPTCNR1
SCHEMBL25110930 0.82 TSHR (0.36) TSHRRECQLGLP1RKMT2AMEN1
SCHEMBL25110640 0.82 TSHR (0.36) TSHRRECQLGLP1RKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 TSHR 3319/4885RECQL 2866/4885GLP1R 2955/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885RECQL 2866/4885GLP1R 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.